Antimicrobial Resistance in Gram-negative bacteria from Urinary Specimens: a study of prevalence, risk factors and molecular mechanisms of resistance (ARGUS) in Zimbabwe - a study protocol.
AMR
Escherichia coli
antibiotic resistance
Journal
Wellcome open research
ISSN: 2398-502X
Titre abrégé: Wellcome Open Res
Pays: England
ID NLM: 101696457
Informations de publication
Date de publication:
2020
2020
Historique:
accepted:
28
05
2020
entrez:
22
10
2020
pubmed:
23
10
2020
medline:
23
10
2020
Statut:
epublish
Résumé
Antimicrobial resistance (AMR) is compromising our ability to successfully treat infections. There are few data on gram-negative AMR prevalence in sub-Saharan Africa especially from the outpatient setting. This study aims to investigate the prevalence of and underlying molecular mechanisms for AMR in gram-negative bacilli causing urinary tract infections (UTIs) in Zimbabwe. Risk factors for AMR and how AMR impacts on clinical outcomes will also be investigated. Adults presenting with UTI symptoms at primary health clinics in Harare will be included. A questionnaire will be administered, and urine samples will be collected for culture. Participants with positive urine cultures will be followed up at 7-14 days post-enrolment. All participants will also be followed by telephone at 28 days to determine clinical outcomes. Bacterial identification and antibiotic susceptibility testing will be performed on positive cultures. The results from this study will be used to inform policy and development of treatment recommendations. Whole genome sequencing results will provide a better understanding of the prevalent resistance genes in Zimbabwe, of the spread of successful clones, and potentially will contribute to developing strategies to tackle AMR.
Identifiants
pubmed: 33088923
doi: 10.12688/wellcomeopenres.15977.1
pmc: PMC7551514
doi:
Types de publication
Journal Article
Langues
eng
Pagination
140Subventions
Organisme : Wellcome Trust
ID : 206316/Z/17/Z
Pays : United Kingdom
Informations de copyright
Copyright: © 2020 Olaru ID et al.
Déclaration de conflit d'intérêts
No competing interests were disclosed.
Références
Open Microbiol J. 2017 Oct 31;11:292-300
pubmed: 29204224
BMC Infect Dis. 2017 Dec 6;17(1):750
pubmed: 29207958
Environ Microbiol. 2009 Dec;11(12):2970-88
pubmed: 19601960
Euro Surveill. 2019 Oct;24(41):
pubmed: 31615598
Int J Med Microbiol. 2017 Oct;307(7):422-429
pubmed: 28789913
Pan Afr Med J. 2017 Jan 30;26:41
pubmed: 28451019
BMJ. 2010 May 18;340:c2096
pubmed: 20483949
Int J Med Microbiol. 2016 Jun;306(4):249-54
pubmed: 27222489
J Glob Antimicrob Resist. 2019 Sep;18:109-114
pubmed: 30685460
Afr Health Sci. 2016 Dec;16(4):1131-1142
pubmed: 28479906
Clin Infect Dis. 2019 Dec 13;:
pubmed: 31832638
Afr J Infect Dis. 2016 May 01;10(2):89-95
pubmed: 28480442
Clin Infect Dis. 2006 Jan 15;42 Suppl 2:S82-9
pubmed: 16355321
Lancet HIV. 2015 Apr;2(4):e137-50
pubmed: 26424674
Lancet Infect Dis. 2018 Dec;18(12):e368-e378
pubmed: 30172580
Antimicrob Agents Chemother. 2010 Nov;54(11):4851-63
pubmed: 20733044
Int J Antimicrob Agents. 2009 Nov;34(5):407-13
pubmed: 19505803
Nat Rev Microbiol. 2015 May;13(5):269-84
pubmed: 25853778
PLoS One. 2019 Sep 26;14(9):e0222651
pubmed: 31557170
Int J Med Microbiol. 2013 Aug;303(6-7):298-304
pubmed: 23499304
Antimicrob Resist Infect Control. 2015 Apr 17;4:12
pubmed: 25908966
J Int Assoc Physicians AIDS Care (Chic). 2009 May-Jun;8(3):165-9
pubmed: 19357424
Trop Med Int Health. 2011 Sep;16(9):1167-79
pubmed: 21707879
Ethiop J Health Sci. 2016 Mar;26(2):93-100
pubmed: 27222621
Pediatr Infect Dis J. 2016 Jul;35(7):e191-8
pubmed: 27031259
BMC Infect Dis. 2013 Jan 18;13:19
pubmed: 23327474
BMC Infect Dis. 2017 Apr 17;17(1):282
pubmed: 28415986
Afr Health Sci. 2014 Dec;14(4):821-8
pubmed: 25834489
J Antimicrob Chemother. 2005 Jul;56(1):52-9
pubmed: 15917288
BMC Infect Dis. 2017 Sep 11;17(1):616
pubmed: 28893183
PLoS One. 2016 Jan 25;11(1):e0147659
pubmed: 26807811
BMC Infect Dis. 2017 Sep 29;17(1):654
pubmed: 28962545
Euro Surveill. 2008 Nov 20;13(47):
pubmed: 19021958
BMC Res Notes. 2018 Dec 17;11(1):901
pubmed: 30558656
J Glob Antimicrob Resist. 2019 Jun;17:173-179
pubmed: 30625416
Ann Clin Microbiol Antimicrob. 2016 Aug 18;15(1):49
pubmed: 27539221
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Clin Infect Dis. 2010 Apr 1;50(7):979-87
pubmed: 20192731
Clin Infect Dis. 2019 Oct 30;69(Suppl 6):S449-S458
pubmed: 31665776
Microbiol Mol Biol Rev. 2010 Sep;74(3):417-33
pubmed: 20805405
Microbiol Spectr. 2016 Apr;4(2):
pubmed: 27227291
Lancet Glob Health. 2017 Mar;5(3):e359-e369
pubmed: 28139443
J Chemother. 2020 Mar 2;:1-4
pubmed: 32114964
Afr J Infect Dis. 2013;7(1):1-7
pubmed: 24381720
Lancet. 2016 Jan 9;387(10014):176-87
pubmed: 26603922
Ethiop J Health Sci. 2015 Jan;25(1):3-8
pubmed: 25733779
BMC Infect Dis. 2016 Oct 17;16(1):570
pubmed: 27751185
S Afr Med J. 2018 Aug 28;108(9):763-771
pubmed: 30182902
Antimicrob Resist Infect Control. 2018 Jan 8;7:4
pubmed: 29340148
Pan Afr Med J. 2017 Mar 22;26:166
pubmed: 28674559
Pan Afr Med J. 2017 Mar 10;26:134
pubmed: 28533857
J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):585-91
pubmed: 18285712
BMC Pediatr. 2019 Jan 26;19(1):32
pubmed: 30684964
Afr J Infect Dis. 2016 Nov 24;11(1):18-25
pubmed: 28337490
Expert Rev Pharmacoecon Outcomes Res. 2005 Aug;5(4):457-66
pubmed: 19807263
Malar J. 2018 Jan 19;17(1):41
pubmed: 29351795
Clin Infect Dis. 2017 Jun 15;64(suppl_3):S368-S377
pubmed: 28575366
Clin Infect Dis. 2012 Apr;54 Suppl 2:S159-64
pubmed: 22403231
BMC Res Notes. 2014 Oct 03;7:687
pubmed: 25280498
BMC Infect Dis. 2020 Jan 30;20(1):86
pubmed: 32000722
PLoS One. 2019 Sep 24;14(9):e0222675
pubmed: 31550295
Afr J Lab Med. 2016 Oct 31;5(3):482
pubmed: 28879138
Infect Drug Resist. 2013 Dec 02;6:225-33
pubmed: 24324344
Biomed Res Int. 2019 Mar 27;2019:3937812
pubmed: 31032344
BMC Med. 2019 Mar 29;17(1):70
pubmed: 30922309
Clin Infect Dis. 2019 Jun 18;69(1):61-68
pubmed: 30277505
J Infect Dev Ctries. 2017 Sep 30;11(9):705-718
pubmed: 31600162
Clin Infect Dis. 2017 Aug 1;65(3):469-476
pubmed: 28444155
Pan Afr Med J. 2017 Nov 23;28:258
pubmed: 29881501